Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for diffuse large B-cell lymphoma after 2 or more systemic treatments:
- Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (2024) NICE technology appraisal guidance 954
- Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (2024) NICE technology appraisal guidance 947
- Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (2023) NICE technology appraisal guidance 927
- Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (2023) NICE technology appraisal guidance 872
This page was last updated: